Drug Trial Radar · NCT07144098
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Aug 12, 2025
Primary completion
Apr 7, 2026
Study completion Apr 7, 2026
Sponsor
- Lead sponsor
- Gan & Lee Pharmaceuticals.Industry
- Sponsor type
- Industry
- First posted
- Aug 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study adopts a multicenter, single-dose, open-label, and parallel design, which is aimed at assessing the PK and safety profiles of GZR18 Injection in subjects with normal liver function and those with mild, moderate or severe liver insufficiency. The study duration for each subject in this study is up to 50 days, including a screening period of up to 14 days (Day-14 to Day-1), an 8-day dosing/observation period (Day 1 to Day 8), and a 28-day follow-up period (Day 9 to Day 36).
Conditions
- Obesity/Overweight
Interventions
GZR18 injectionDrug
3 mg-Control group
GZR18 injectionDrug
3 mg-mild liver insufficiency
GZR18 injectionDrug
3 mg-moderate liver insufficiency
GZR18 injectionDrug
3 mg-severe liver insufficiency
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax:Maximum plasma concentration.Time frame: through study completion, an average of 36 days
- AUC0-last:Area under the plasma concentration-time curve at 0 h to last observation time-point after a single dose.Time frame: through study completion, an average of 36 days
- AUC0-inf:Area under the plasma concentration-time curve at 0 h to infinity after a single dose.Time frame: through study completion, an average of 36 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gan & Lee Pharmaceuticals
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.